Feinstein Institutes Link Brain Tumor Growth to Metabolic Flaw, Proposing Short-Term Dietary Intervention
Researchers at the Feinstein Institutes for Medical Research have identified a metabolic link between high-grade gliomas and a rare genetic disorder called GAMT deficiency. By restricting specific amino acids, particularly arginine, and adding ornithine, the team successfully slowed tumor growth in mice. This dietary approach, which must be medically supervised, aims to reduce the production of a toxic chemical that fuels tumor expansion. A clinical trial for humans is planned to begin in 2027, potentially allowing patients to alter their diet for just three to five days before surgery to improve outcomes.
